ID   LO68
AC   CVCL_2581
DR   BioSample; SAMN07624410
DR   BioSamples; SAMEA100921
DR   cancercelllines; CVCL_2581
DR   CBA; CBA-0141
DR   Cosmic; 1522778
DR   Cosmic; 1963330
DR   DepMap; ACH-001547
DR   ECACC; 10092311
DR   GEO; GSM726273
DR   Progenetix; CVCL_2581
DR   Wikidata; Q54902877
RX   PubMed=1703129;
RX   PubMed=21642991;
RX   PubMed=25902174;
RX   PubMed=27605433;
RX   PubMed=28387650;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Transformant: ChEBI; CHEBI:46666; Crocidolite asbestos.
CC   Omics: Exosome proteome analysis.
CC   Omics: Secretome proteome analysis.
CC   Omics: SNP array analysis.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): CBA=CBA-0141
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11
ST   D16S539: 10,12
ST   D18S51: 12,15
ST   D19S433: 13,15.2
ST   D21S11: 30,30.2
ST   D2S1338: 20,24
ST   D3S1358: 16,18
ST   D5S818: 11,13
ST   D7S820: 8,10
ST   D8S1179: 14
ST   FGA: 20,22
ST   TH01: 8,9
ST   TPOX: 8,11
ST   vWA: 17,18
DI   NCIt; C45662; Pleural epithelioid mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   57Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 20
//
RX   PubMed=1703129; DOI=10.1002/ijc.2910470219;
RA   Manning L.S., Whitaker D., Murch A.R., Garlepp M.J., Davis M.R.,
RA   Musk A.W., Robinson B.W.S.;
RT   "Establishment and characterization of five human malignant
RT   mesothelioma cell lines derived from pleural effusions.";
RL   Int. J. Cancer 47:285-290(1991).
//
RX   PubMed=21642991; DOI=10.1038/ng.855; PMCID=PMC4643098;
RA   Bott M.J., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L.,
RA   Creaney J., Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R.,
RA   Powell S.N., Zhou Q., Shen R.-L., Olshen A.B., Rusch V.W., Ladanyi M.;
RT   "The nuclear deubiquitinase BAP1 is commonly inactivated by somatic
RT   mutations and 3p21.1 losses in malignant pleural mesothelioma.";
RL   Nat. Genet. 43:668-672(2011).
//
RX   PubMed=25902174; DOI=10.1097/JTO.0000000000000493;
RA   Miyanaga A., Masuda M., Tsuta K., Kawasaki K., Nakamura Y., Sakuma T.,
RA   Asamura H., Gemma A., Yamada T.;
RT   "Hippo pathway gene mutations in malignant mesothelioma: revealed by
RT   RNA and targeted exon sequencing.";
RL   J. Thorac. Oncol. 10:844-851(2015).
//
RX   PubMed=27605433; DOI=10.1038/srep32643; PMCID=PMC5015102;
RA   Greening D.W., Ji H., Chen M.-S., Robinson B.W.S., Dick I.M.,
RA   Creaney J., Simpson R.J.;
RT   "Secreted primary human malignant mesothelioma exosome signature
RT   reflects oncogenic cargo.";
RL   Sci. Rep. 6:32643-32643(2016).
//
RX   PubMed=28387650; DOI=10.21873/cgp.20023; PMCID=PMC5369310;
RA   Creaney J., Dick I.M., Leon J.S., Robinson B.W.S.;
RT   "A proteomic analysis of the malignant mesothelioma secretome using
RT   iTRAQ.";
RL   Cancer Genomics Proteomics 14:103-117(2017).
//